Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS-Reference-Cited by-同舟云学术

Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS

Published:2022-04-13 Issue:16 Volume:94 Page:6297-6303
ISSN:0003-2700
Container-title:Analytical Chemistry
language:en
Short-container-title:Anal. Chem.

Author:

Callens Celine¹^ORCID,Bidard Francois-Clement²³,Curto-Taribo Anaïs¹,Trabelsi-Grati Olfa¹,Melaabi Samia¹,Delaloge Suzette⁴,Hardy-Bessard Anne-Claire⁵,Bachelot Thomas⁶,Clatot Florian⁷,De La Motte Rouge Thibault⁸,Canon Jean-Luc⁹,Arnould Laurent¹⁰,Andre Fabrice⁴,Marques Sandrine¹¹,Stern Marc-Henri¹²,Pierga Jean-Yves³¹³,Vincent-Salomon Anne¹⁴,Benoist Camille¹⁵,Jeannot Emmanuelle¹,Berger Frederique¹⁶,Bieche Ivan¹,Pradines Anne¹⁷¹⁸

Affiliation:

1. Pharmacogenomic Unit, Genetics Laboratory, Department of Diagnostic and Theranostic Medicine, Institut Curie and PSL University, 75005 Paris, France

2. Department of Medical Oncology, Institut Curie, UVSQ/Paris Saclay University, 92210 Saint Cloud, France

3. Circulating Tumor Biomarkers Laboratory, Inserm CIC-BT 1428, Institut Curie, 75005 Paris, France

4. Department of Medical Oncology, Gustave Roussy, 94800 Villejuif, France

5. Department of Medical Oncology, Centre Armoricain d’Oncologie, 22190 Plérin, France

6. Department of Medical Oncology, Centre Léon Bérard, 69000 Lyon, France

7. Department of Medical Oncology, Centre Henri Becquerel, 76000 Rouen, France

8. Department of Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France

9. Department of Medical Oncology, Grand Hôpital de Charleroi, 6000 Charleroi, Belgique

10. Department of Pathology, Centre Georges François Leclerc, 21000 Dijon, France

11. Research and Development Department, UNICANCER, 75013 Paris, France

12. Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.) Team, Institut Curie, PSL Research University, 75005 Paris, France

13. Department of Medical Oncology, Institut Curie & Université de Paris, 75005 Paris, France

14. Department of Diagnostic and Theranostic Medicine, Institut Curie, 75005 Paris, France

15. Bio-informatic Clinical Unit, Department of Diagnostic and Theranostic Medicine, Institut Curie and PSL University, 75005 Paris, France

16. Biometry Unit, Institut Curie and PSL Research University, 75005 Paris and 92210 Saint-Cloud, France

17. INSERM U1037 CNRS ERL5294 UPS, Cancer Research Center of Toulouse, 31000 Toulouse, France

18. Prospective Biology Unit, Medical Laboratory, Claudius Regaud Institute, Toulouse University Cancer Institute (IUCT-O), 31000 Toulouse, France

Funder

Pfizer

Minist?re des Affaires Sociales et de la Sant?

Institut National Du Cancer

Publisher

American Chemical Society (ACS)

Subject

Analytical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.analchem.2c00446

Reference20 articles.

1. ESR1 mutations: a new biomarker in breast cancer

2. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

3. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer

4. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

5. D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gene point mutation information translation and detection: Leveraging single base extension and CRISPR/Cas12a;Biosensors and Bioelectronics;2024-03

2. Rational thresholding of circulating tumor DNA concentration for improved surveillance of metastatic breast cancer;ESMO Open;2024-02

3. Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma;BMC Cancer;2023-11-03

4. ESR1 Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?;Cancers;2023-10-27

5. Development of sensitive and robust multiplex digital PCR assays for the detection of ESR1 mutations in the plasma of metastatic breast cancer patients;Clinica Chimica Acta;2023-05